Tetracycline Provocation in Lupus Erythematosus

This is the authors' abstract. We don't add key points for this paper.

Article1 May 1959TETRACYCLINE PROVOCATION IN LUPUS ERYTHEMATOSUSCASIMIR A. DOMZ, M.D., F.A.C.P., DELBERT H. MCNAMARA, M.D., F.A.C.P., HANS F. HOLZAPFEL, M.D.CASIMIR A. DOMZ, M.D., F.A.C.P.Search for more papers by this author, DELBERT H. MCNAMARA, M.D., F.A.C.P.Search for more papers by this author, HANS F. HOLZAPFEL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-50-5-1217 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHypersensitivity is largely responsible for the unpredictability of lupus erythematosus (L. E.). The unwary physician, and even the wary one, may prescribe a necessary drug only to see devastation wreaked by a violent hypersensitivity reaction. Such a reaction may be the first intimation of the presence of L. E., it may herald accelerated systemic spread in discoid lupus, or it may be the final disastrous turn in the course of a patient with systemic lupus erythematosus. When such a reaction occurs, the physician's 20/20 hindsight is small comfort to him, and of little use to the patient. The purpose of...Bibliography1. Caplan A: Unusual radiologic appearances in chest of coal miners suffering from rheumatoid arthritis, Thorax 8: 29-37 (Mar.) 1953. CrossrefMedlineGoogle Scholar2. StokesMadden JHJF: Acute disseminated lupus erythematosus, Arch. Dermat. and Syph. 25: 854-875 (May) 1932. CrossrefGoogle Scholar3. Fox RA: Disseminated lupus erythematosus—an allergic disease? Arch. Path. 36: 311-315 (Sept.) 1943. Google Scholar4. Teilum G: Hyperglobulinemia, periarterial fibrosis of the spleen, and the wire loop lesion in disseminated lupus erythematosus in relation to allergic pathogenesis, Am. J. Path. 24: 409-428 (Mar.) 1948. MedlineGoogle Scholar5. Ehrich WE: Nature of collagen diseases, Am. Heart J. 43: 121-156 (Jan.) 1952. CrossrefMedlineGoogle Scholar6. Berk NG: The role of hypersensitivity in the pathogenesis of disseminated lupus erythematosus, Am. Pract. 8: 54-60 (Jan.) 1957. Google Scholar7. Haserick JR: Modern concepts of systemic lupus erythematosus: a review of 126 cases, J. Chron. Dis. 1: 317-334 (Mar.) 1955. CrossrefMedlineGoogle Scholar8. RosePillsbury EDM: Acute disseminated lupus erythematosus—a systemic disease, Ann. Int. Med. 12: 951-963 (Jan.) 1939. LinkGoogle Scholar9. Kierland RR: Classification and cutaneous manifestations of lupus erythematosus, Proc. Staff Meet., Mayo Clin. 15: 675-677 (Oct. 23) 1940. Google Scholar10. SchiffKern BLAB: Discoid lupus erythematosus following trauma, Brit. J. Dermat. 66: 357-360 (Oct.) 1954. CrossrefMedlineGoogle Scholar11. Bernstein ET: Lupus erythematosus following laceration by broken glass, Arch. Dermat. and Syph. 63: 261-263 (Feb.) 1951. CrossrefGoogle Scholar12. Keil H: Conception of lupus erythematosus, and its morphologic variants, Arch. Dermat. and Syph. 36: 729-757 (Oct.) 1937. CrossrefGoogle Scholar13. AyvazianBadger LFTL: Disseminated lupus erythematosus occurring among student nurses, New England J. Med. 239: 565-570 (Oct. 14) 1948. CrossrefMedlineGoogle Scholar14. WalshZimmerman JRHJ: The demonstration of the L. E. phenomenon in patients with penicillin hypersensitivity, Blood 8: 65-71 (Jan.) 1953. CrossrefMedlineGoogle Scholar15. MiescherDelacretaz PJ: Démonstration d'un phénomène "L. E." positif dans deux cas d'hypersensibilité médicamenteuse, Schweiz. med. Wchnschr. 83: 536-538 (June 6) 1953. MedlineGoogle Scholar16. Lindqvist T: Lupus erythematosus disseminatus after administration of mesantoin, Acta med. Scandinav. 158: 131-138 (June) 1957. CrossrefMedlineGoogle Scholar17. CastlemanMandelbaum LRA: Gold poisoning and disseminated lupus, Am. Pract. 1: 561-569 (June) 1950. Google Scholar18. Ogryzlo MA: Diffuse systemic rheumatoid disease, Ann. Rheumat. Dis. 12: 323-326 (Dec.) 1953. Google Scholar19. SlocumbPolleyWardHench CHHFLEPS: Diagnosis, treatment and prevention of chronic hypercortisonism in patients with rheumatoid arthritis, Ann. Int. Med. 46: 86-101 (Jan.) 1957. LinkGoogle Scholar20. PerrySchroeder JMHA: Syndrome simulating collagen disease caused by hydralazine (Apresoline), J. A. M. A. 154: 670-673 (Feb. 20) 1954. CrossrefMedlineGoogle Scholar21. DustanTaylorCorcoranPage HDRDACIH: Rheumatic and febrile syndromes during prolonged hydralazine treatment, J. A. M. A. 154: 23-29 (Jan. 2) 1954. CrossrefMedlineGoogle Scholar22. Gold S: Role of sulphonamides and penicillin in the pathogenesis of systemic lupus erythematosus, Lancet 1: 268-272 (Feb. 3) 1951. CrossrefMedlineGoogle Scholar23. Honey M: Systemic lupus erythematosus presenting with sulphonamide hypersensitivity reaction, Brit. M. J. 1: 1272-1275, 1956. CrossrefMedlineGoogle Scholar24. Paull AM: Occurrence of the L. E. phenomenon in a patient with a severe penicillin reaction, New England J. Med. 252: 128-129, 1955. CrossrefMedlineGoogle Scholar25. ComensSchroeder PHA: The L. E. cell as a manifestation of delayed hydralazine intoxication, J. A. M. A. 160: 1134-1136, 1956. CrossrefMedlineGoogle Scholar26. Dubois EL: The effect of the L. E. cell test on the clinical picture of systemic lupus erythematosus, Ann. Int. Med. 38: 1265-1294 (Aug.) 1953. LinkGoogle Scholar27. HarveySchulmanTumultyConleySchoenrich AMLEPACLEH: Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases, Medicine 33: 291-437 (Dec.) 1954. CrossrefMedlineGoogle Scholar28. GoldGowing SCNF: Systemic lupus erythematosus; a clinical and pathological study, Quart. J. Med. 46: 457-481 (Oct.) 1953. Google Scholar29. BermanAxelrodGoodmanMcLaughry LARHLRI: So-called "lupus erythematosus inclusion phenomenon" of bone marrow and blood; morphologic and serologic studies, Am. J. Clin. Path 20: 403-418, 1950. CrossrefMedlineGoogle Scholar30. LeeMichaelVural SLSRIL: L. E. (lupus erythematosus) cell; clinical and chemical studies, Am. J. Med. 10: 446-451 (Apr.) 1951. CrossrefMedlineGoogle Scholar31. MontgomeryMcCreight HWG: Disseminate lupus erythematosus, Arch. Dermat. and Syph. 60: 356-372 (Sept.) 1949. CrossrefGoogle Scholar32. WeissSwift RSS: The significance of a positive L. E. phenomenon, Arch. Dermat. and Syph. 72: 103-112 (Aug.) 1955. CrossrefGoogle Scholar33. FisherMoyer GSJB: Hematologic phenomena as test for acute disseminated lupus erythematosus, Grace Hosp. Bull. 28: 3-9 (Jan.) 1950. MedlineGoogle Scholar34. SiegelFriedmanKesslerSchwartz BMIASSO: Thrombohemolytic thrombocytopenic purpura and lupus erythematosus, Ann. Int. Med. 47: 1022-1029 (Nov.) 1957. LinkGoogle Scholar35. JoskeKing RAWE: The L. E.-cell phenomenon in active chronic viral hepatitis, Lancet 2: 477-480 (Sept. 3) 1955. CrossrefGoogle Scholar36. HellerZimmermanRozengvaigSinger PHJSK: The L. E.-cell phenomenon in chronic hepatic disease, New England J. Med. 254: 1160-1165 (June 21) 1956. CrossrefMedlineGoogle Scholar37. Bettley FR: "L. E.-cell" phenomenon in active chronic viral hepatitis, Lancet 2: 724 (Oct. 1) 1955. CrossrefGoogle Scholar38. Jacobs AG: A false-positive lupus erythematosus test, Ann. Int. Med. 42: 1097-1100 (May) 1955. LinkGoogle Scholar39. ArnoldTilden HLIL: Fatal scleroderma with L. E. phenomenon, Arch. Dermat. and Syph. 76: 427-430 (Oct.) 1957. CrossrefGoogle Scholar40. LincolnRicker MWA: A case of periarteritis nodosa with L. E. cells, Ann. Int. Med. 41: 639-646 (Sept.) 1954. LinkGoogle Scholar41. KievitsGoslingsSchmitHymens JHJREW: Rheumatoid arthritis and the positive L. E.-cell phenomenon, Ann. Rheumat. Dis. 15: 211-216 (Sept.) 1956. CrossrefMedlineGoogle Scholar42. FriedmanSickleyPoskeBlackBronskyHartzFeldhakeReederKatz IAJFRMADWHCPSEM: The L. E. phenomenon in rheumatoid arthritis, Ann. Int. Med. 46: 1113-1136 (June) 1957. LinkGoogle Scholar43. Butterworth CE: The production of L. E. cells in normal individuals, J. Clin. Investigation 32: 558 (June) 1953. Google Scholar44. BrunsonDavis JGRL: Systemic fibrinoid diseases, Arch. Path. 60: 593-609 (Dec.) 1955. Google Scholar45. Symposium on lupus erythematosus, Proc. Staff Meet., Mayo Clin. 15: 675-688 (Oct. 23) 1940. Google Scholar46. SvanborgSolvell AL: Incidence of disseminated lupus erythematosus, follow-up studies indicating increased frequency, J. A. M. A. 165: 1126-1128 (Nov. 2) 1957. CrossrefMedlineGoogle Scholar47. Tumulty PA: The clinical course of systemic lupus erythematosus, J. A. M. A. 156: 947-953 (Nov. 6) 1954. CrossrefMedlineGoogle Scholar48. BernsteinLustberg ILA: Penicillin anaphylaxis occurring in a patient on steroid therapy, Ann. Int. Med. 47: 1276-1279 (Dec.) 1957. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Santa Barbara, California*Received for publication February 11, 1958.Presented at the Southern California Regional Meeting of The American College of Physicians, Riverside, California, February 22, 1958.From the Departments of Internal Medicine, The Sansum Medical Clinic and Santa Barbara Cottage Hospital, Santa Barbara, California.Requests for reprints should be addressed to Casimir A. Domz, M.D., The Sansum Medical Clinic, 317 West Pueblo Street, Santa Barbara, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTetracyclinesAnaphylaxis to mefenamic acid in a patient with new onset of systemic lupus erythematosusDrug ReactionsANTIBACTERIAL DRUGSSulpha allergy in lupus patients: a clinical perspectiveTetracyclinesTetracyclines in dermatologyTetracyclines in dermatologyLes lupus induits par les médicamentsTetracyclines and autoimmunityRéactions systémiques secondaires à la prise de minocycline. À propos de quatre observations et revue de la littératureHépatite auto-immune et syndrome lupique secondaires à la prise de minocylineDrug-Induced Lupus ErythematosusTetracyclines and their uses in dermatologyMinocycline-Induced LupusMinocycline-related lupus erythematosus with associated liver diseaseMinocycline-associated lupus erythematosusMinocycline-related lupusHyperpigmentation, neutrophilic alveolitis, and erythema nodosum resulting from minocyclineErythema multiforme occurring in association with lupus erythematosus during therapy with doxycyclineTetracyclines-how safe are they?Transglutaminase may mediate certain physiological effects of endogenous amines and of amine-containing therapeutic agentsPulmonary Infiltrates with Eosinophilia Associated with TetracyclineMedikamentös induzierter systemischer Lupus erythematodesDie relevanten Sachverhalte der Umwandlung und der Übertragung einzelner Wirtschaftsgüter nach den Grundsätzen einer steuerneutralen BehandlungDrug-Induced Systemic Lupus Erythematosus and Related SyndromesDrug-induced systemic lupus erythematosus: A critical reviewTetracycline-Induced Immune Hemolytic AnemiaCurrent Therapeutic Concepts–Drug-Induced DiseasesProcainamide-induced lupus erythematosusTETRACYCLINE TOXICITY IN RENAL FAILUREA LUPUS‐LIKE REACTION TO ANTITUBER‐CULOSIS DRUGSAntinuclear Antibodies Following Hydralazine ToxicityHYDRALAZINE (APRESOLBNE) LUPUS WITH FATAL RENAL FAILURETetracycline-Induced AzotemiaLupus erythematosus cell phenomenon in patients with chronic ulcerative colitisSystemic lupus erythematosusAcute Hepatitis and the Lupus Erythematosus PhenomenonAcute glutethimide intoxicationPulmonary disease and rapidly progressive renal failurePararheumatische Krankheiten (Sogenannte Kollagenkrankheiten) 1 May 1959Volume 50, Issue 5Page: 1217-1226KeywordsArthralgiaArthritisFibrosisHospital medicineHypersensitivityLupus erythematosusPharyngitisStreptococcal pharyngitisTetracyclinesUrticaria ePublished: 1 December 2008 Issue Published: 1 May 1959 PDF downloadLoading ...